Gilead Subsidiary to Launch Authorized Generics of Epclusa® (Sofosbuvir/Velpatasvir) and Harvoni® (Ledipasvir/Sofosbuvir) for the Treatment of Chronic Hepatitis C
Gilead Sciences, Inc. (NASDAQ: GILD) announced today plans to launch authorized generic versions of Epclusa® (sofosbuvir 400mg/velpatasvir 100mg) and Harvoni® (ledipasvir 90mg/sofosbuvir 400mg), Gilead’s leading treatments for chronic hepatitis C virus (HCV), in the United States, through a newly created subsidiary, Asegua Therapeutics LLC. The authorized generics will launch at a list price of $24,000 for the most common course of therapy and will be available in January 2019.
Since the launch of Gilead’s first HCV medication in 2013, the average price paid for each bottle of medicine in the United States has decreased by more than 60 percent off of the public list prices, across health insurers and government payers. Due to the complexity and structure of the U.S. healthcare system, however, these discounts provided by Gilead may not always translate into lower costs for patients. Further, existing contracts, together with laws associated with government pricing policies, make it challenging to quickly lower a product’s list price once it is on the market.
The authorized generics are priced to more closely reflect the discounts that health insurers and government payers receive today. Insurers will have the choice of offering either the authorized generics or the branded medications for both Epclusa and Harvoni. In the Medicare Part D setting, the authorized generics could save patients up to $2,500 in out-of-pocket costs per course of therapy. The authorized generics will also offer substantial savings to state managed Medicaid plans that do not currently benefit from negotiated rebates and that represent a significant number of people in need, potentially opening up access to our medications to beneficiaries who were previously denied coverage.
“Launching these authorized generics is the best solution available to us today to quickly introduce a lower-priced alternative to our HCV medications without significant disruption to the healthcare system and our business,” said John F. Milligan, PhD, President and Chief Executive Officer, Gilead Sciences. “This launch also will hopefully help increase transparency by more closely aligning our medications’ list prices with their cost. Our ultimate goal is to lower the list price of Epclusa – a medication we believe is of great importance given its clinical profile across genotypes – and Harvoni. We are committed to working with all of our partners in the healthcare system to help enable list price reductions of our HCV medications and find better solutions to reduce patients’ out-of-pocket costs.”
Beyond the company’s efforts to reduce patient costs, Gilead is continuing to pursue innovative collaborations and long-term financing models, such as a potential subscription model, that could not only expand access, but aim to eliminate HCV in the United States and around the world.
About Gilead Sciences, Inc.
Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The company strives to transform and simplify care for people with life-threatening illnesses around the world. Gilead has operations in more than 35 countries worldwide, with headquarters in Foster City, California.
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks, uncertainties and other factors that could cause actual results to differ materially from those referred to in the forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. These and other risks are described in detail in Gilead’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2018, as filed with the U.S. Securities and Exchange Commission. All forward-looking statements are based on information currently available to Gilead, and Gilead assumes no obligation to update any such forward-looking statements.
For more information on Gilead Sciences, please visit the company’s website at www.gilead.com , follow Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.
Gilead Sciences, Inc.
Sung Lee, 650-524-7792
Amy Flood, 650-522-5643
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
Arthur D. Little Appoints Michael Kruse as Head of Global Energy & Utilities Practice23.4.2019 12:42:00 EEST | Tiedote
Arthur D. Little (ADL) today announced the appointment of Michael Kruse as the new Global Practice Leader for its Global Energy & Utilities practice. A Partner based in ADL’s Frankfurt office, Michael has been with the company for over 11 years, focusing on the strategy and project development behind large-scale capital investment programs in the power sector, including conventional and renewable energies, as well as power grids. His most recent consulting work explored the future of nuclear generation, offshore wind and corporate transformation in the digital era. ADL’s Global Energy and Utilities practice works together with its clients as partners to apply clear thinking to their key strategic issues. It offers a unique ability to combine four factors: a deep, practical understanding of the energy industry and its most difficult challenges, the highest caliber of people, innovation to produce fresh insight, and a commitment to achieving measurable results. Ignacio García Alves, Chai
The New myPOS Go is Here to Become a Market Leader at Just 29 EUR23.4.2019 12:25:00 EEST | Tiedote
Europe’s fastest growing payments provider, myPOS, today announces the upcoming launch of its latest payment terminal - myPOS Go. Portable and light-weighted, myPOS Go boasts a list of innovative functionalities, emblematic for all myPOS devices – from accepting cards and mobile wallets to sending payment requests and topping up prepaid phones and branded gift cards. At just 29 EUR, merchants will get the new payment device with a free myPOS account and business debit card to it for immediate use of the acquired funds, which are settled instantly after every received payment. The payment terminal is pocket-sized, paperless and perfect for merchants on the go, who seek independence from traditional banks. "Designing payment services with the small and micro businesses in mind, we are aware that some merchants are really sensitive to the cost of payment terminals. Although we do not charge any monthly fees in addition to the device cost, we would like to cater to those merchants and offe
Samsung Sets New Photon Efficacy Level in White LED Packages for Indoor Farms23.4.2019 12:00:00 EEST | Tiedote
Samsung Electronics Co., Ltd., a world leader in advanced digital component solutions, today announced an industry-leading enhancement to its mid-power LED package – the LM301H – for horticulture applications, such as greenhouse and vertical farming*. At 3.10 micromoles per joule (μmol/J), the newly introduced LM301H now features the highest photon efficacy** among today’s mid-power white LED packages. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190423005400/en/ Samsung Horticulture LED LM301H (Photo: Business Wire) “This breakthrough in photon efficacy will go a long way in helping indoor farm owners to maximize plant growth and quality, as well as their profits,” said Un Soo Kim, senior vice president of LED Business Team at Samsung Electronics. “We are committed to continue innovating white LED solutions optimized for healthier plant production as we solidify our leadership in the horticulture lighting industry.” As a
Vivet Therapeutics Announces 2 Abstracts Accepted for Oral Presentation at 2019 American Society of Gene and Cell Therapy Annual Meeting23.4.2019 11:38:00 EEST | Tiedote
Vivet Therapeutics (“Vivet”), a privately held gene therapy biotech company dedicated to developing gene therapy treatments for inherited liver disorders with high unmet medical need, today announced that new data from its lead development program, VTX-801 a novel investigational gene therapy for WD, and VTX-803, Vivet’ novel therapeutic in development for the treatment of PFIC3, have been accepted for oral presentation during the ASGCT 22nd Annual Meeting, April 29 - May 2, 2019 in Washington, D.C., USA. Dr. Gloria González-Aseguinolaza, Vivet Therapeutics CSO & Head of the Gene Therapy Dept. at FIMA will present data from a recently completed study, validating in WD mice the use of fecal excretion of IV-injected 64copper as a pharmacodynamic endpoint in the VTX-801 Phase I/II trial currently under preparation. These data are the first demonstration of copper homeostasis restoration with 64Copper in an animal model of WD through the delivery of a single, intravenous administration of
Transphorm Centers on the Simplicity and Reliability of High Voltage GaN Application Development at PCIM 201923.4.2019 11:00:00 EEST | Tiedote
Transphorm Inc.—the leader in the design and manufacturing of the highest reliability and first JEDEC- and AEC-Q101 qualified 650 V and 900 V gallium nitride (GaN) semiconductors—today shared a glimpse into its 2019 PCIM Europe showcase. Located in Hall 9 Booth 519, it centers on three key points to help conference attendees better understand Transphorm’s high voltage GaN value proposition: Reliability: Design with confidence when using Transphorm’s high quality, high reliability (Q+R) GaN transistors. Drivability: Pair Transphorm’s devices with off-the-shelf drivers, for easing drivability. Simplicity: Experience simpler designs due to minimal external gate drive circuitry along with standard packages, such as TO-220, TO-247, and PQFN, with well-known thermal management techniques. “At PCIM, you’ll see the culmination of Transphorm’s innovation along with its measurable impact on low volume as well as high volume customer applications,” said Philip Zuk, Vice President, Technical Marke
PV InfoLink to Host Dialogues with Industry Heavyweights on 2H19 Solar Market Outlook Prior To SNEC23.4.2019 10:00:00 EEST | Tiedote
A seminar titled “2H19 PV Market Outlook and Forecast” will be held in Shanghai on June 3, one day prior to SNEC, to discuss global supply chain market outlook in the second half of this year. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190423005391/en/ 2019 Module Prices and Demand Forecast. (Photo: Business Wire) Held by PV InfoLink, a leading solar market intelligence provider, the seminar will bring together PV manufacturers, developers, EPC, and investors to explore major issues revolving the industry and help participants gain valuable insights for navigating the expanding solar market. PV InfoLink has invited Chinese major companies, including Jinko, Longi, and GCL-Si, to discuss impact of China’s transition to a subsidy-free market. This year, China’s demand will revive later than usual due to policy uncertainty. Moreover, Japan and India, China’s two major trading partners, saw weakening demand after the end of f
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme